| Model Number |
EVPROPLUS-26US |
| Medical Device Problem Code |
Intravalvular regurgitation (4068)
|
| Health Effect - Clinical Code |
Aortic Valve Insufficiency/ Regurgitation (4450)
|
| Date of Event |
07/29/2026
|
|
Type of Reportable Event
|
Serious Injury
|
|
Event or Problem Description
|
|
Additional information was received indicating that the patient is being evaluated for whether treatment is needed.
|
| |
|
Event or Problem Description
|
|
It was reported that 4 years and 10 months following implantation of a transcatheter aortic valve, moderate central regurgitation was identified.Subsequently, the patient was hospitalized.
|
| |
|
Additional Manufacturer Narrative
|
|
Image review: a case report and one 3mensio video clip from imaging services dated 07/29/2026 were provided.Report review: the patient is reported to have a 26 mm evolut pro+ valve implanted in september 2021.Evolut appears under expanded.Calcification is present outside the tav frame in the native non-coronary cusp (ncc) at approximately node 2/9.0 mm.Calcification is also seen within the tav frame.Possible pannus, thrombus, or inadequate contrast filling is noted within the tav frame at approximately 12.7 mm.Implant depth measures approximately 5.6 mm beneath the left coronary cusp (lcc) and 5.7 mm beneath the right coronary cusp (rcc).3mensio video clip review: the video clip scrolls through the computed tomography (ct) anatomy from the evolut inflow to outflow and confirms the findings described in the report.Updated b.5 and h.6 medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Search Alerts/Recalls
|